Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference